The CannX Advantage
A rapidly growing and evolving field, medical cannabis is taking center-stage for scientists, clinicians, entrepreneurs, investors, policy makers and thought leaders around the globe. First-hand knowledge and networks are essential in understanding the way forward within this complex ecosystem. CannX is the ultimate place to gain a deep understanding of what is truly ground-breaking in research, business, agriculture and technology. It is where connections are formed, ideas are exchanged, and opportunities move forward.
Confirmed Sponsors and Exhibitors
Program Partners
Media Partners
Three Dynamic Tracks
Explore sessions from three dynamic tracks, covering the full-range of topics essential for all leaders in today’s medical cannabis scene.
SCI
Access the cutting-edge science driving the next wave of developments. Noted researchers and practitioners will present their latest findings.
BIZ
Gain unparalleled insight into the future of business for local and global markets. We will delve into opportunities, pitfalls and the how-to for smart-investments in medical cannabis.
AGR
Stay ahead of competition as the world supply chain develops. CannX will feature new technology, systems and solutions designed to help farmers succeed.
Meet the Committee
Prof. Raphael Mechoulam
Institute for Drug Research, The Hebrew University of Jerusalem, IsraelProf. Raphael Mechoulam
Institute for Drug Research, The Hebrew University of Jerusalem, Israel
Dr. Ilya Reznik, M.D.
Board-certified specialist in Adult Forensic & Clinical NeuroPsychiatry at MaReNa Diagnostic and Consulting Center, IsraelDr. Ilya Reznik, M.D.
Board-certified specialist in Adult Forensic & Clinical NeuroPsychiatry at MaReNa Diagnostic and Consulting Center, Israel
Dr. David (Dedi) Meiri, Ph.D
Head of Scientific Advisory Board Assistant Professor, Heads the ``Laboratory of Cancer Biology and Cannabinoid Research`` Technion, Institute of Technology, IsraelDr. David (Dedi) Meiri, Ph.D
Head of Scientific Advisory Board Assistant Professor, Heads the ``Laboratory of Cancer Biology and Cannabinoid Research`` Technion, Institute of Technology, Israel
Dr. Shaul Lev-Ran, MHA
Deputy Director, Lev Hasharon Medical Center Director of Addiction Medicine and Dual Disorders Clinic, Lev Hasharon Medical Center, Sackler Faculty of Medicine, Tel Aviv University, IsraelDr. Shaul Lev-Ran, MHA
Deputy Director, Lev Hasharon Medical Center Director of Addiction Medicine and Dual Disorders Clinic, Lev Hasharon Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
Dr. Orit Stolar
Pediatric Neurologist, Assaf Harofeh Medical CenterDr. Orit Stolar
Pediatric Neurologist, Assaf Harofeh Medical Center
Dr. Yossi (Joseph) Tam
Head, Obesity and Metabolism Laboratory The Institute for Drug Research, Faculty of Medicine ,Director, Multidisciplinary Center on Cannabinoid Research The Hebrew University of Jerusalem, IsraelDr. Yossi (Joseph) Tam
Head, Obesity and Metabolism Laboratory The Institute for Drug Research, Faculty of Medicine ,Director, Multidisciplinary Center on Cannabinoid Research The Hebrew University of Jerusalem, Israel
Dr. Nirit Bernstein
Dr. Nirit Bernstein Department Head, Soil Physics and irrigation Institute of Soil Water and Environmental Sciences Volcani Center, IsraelDr. Nirit Bernstein
Dr. Nirit Bernstein Department Head, Soil Physics and irrigation Institute of Soil Water and Environmental Sciences Volcani Center, Israel
Dr. Adi Aran
Director of the Neuro-pediatric unit, Shaare Zedek Medical Center , Jerusalem, IsraelDr. Adi Aran
Director of the Neuro-pediatric unit, Shaare Zedek Medical Center , Jerusalem, Israel
Prof. Gil Bar-Sela
Head Cancer Center, Emek Medical Center Afula, IsraelProf. Gil Bar-Sela
Head Cancer Center, Emek Medical Center Afula, IsraelSpeakers
Arnon Afek
Associate Director General, Sheba Medical Center, Acting Chief Physician, Israeli Medical Cannabis Agency, Ministry of Health, IsraelArnon Afek
Associate Director General, Sheba Medical Center, Acting Chief Physician, Israeli Medical Cannabis Agency, Ministry of Health, Israel
Philippe Lucas
VP, Global Patient Research & Access, Tilray Social Dimensions of Health, University of Victoria Graduate Researcher, Canadian Institute for Substance Use Research, CanadaPhilippe Lucas
VP, Global Patient Research & Access, Tilray Social Dimensions of Health, University of Victoria Graduate Researcher, Canadian Institute for Substance Use Research, Canada
Raphael Mechoulam
Prof., Institute for Drug Research, The Hebrew University of Jerusalem, IsraelRaphael Mechoulam
Prof., Institute for Drug Research, The Hebrew University of Jerusalem, Israel
Jonathan Page
PhD, Chief Science Officer, Aurora Cannabis Inc., CanadaJonathan Page
PhD, Chief Science Officer, Aurora Cannabis Inc., Canada
